Merck Poised To Be First To Market With A PD-1 For First-Line Lung Cancer

Merck’s Keytruda improved progression-free survival and overall survival in previously untreated non-small cell lung cancer patients in the highly-anticipated KEYNOTE-024 trial, all but guaranteeing a rapid FDA approval in the indication.